Supplemental Figure 4 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

<p>Overall survival in the subgroup of patients not receiving allogeneic cell transplantation (HCT) based on (A) monocytic vs. non-monocytic differentiation, (B) monocytic differentiation and NPM1 mutation status, (C) in the subgroup of patients with RAS pathway and FLT3-ITD mutations (K/NRAS, PTPN11, FLT3-ITD) and wild-type IDH1/2, NPM1, and TP53; (D) within the patient subgroup classified as mPRS higher-benefit (wild-type for FLT3, N/KRAS and TP53). Reported p-values utilized the cox model Wald test.</p>

Authors

Publication Details

Published
2025-09-03
DOI
https://doi.org/10.1158/2643-3230.30040836
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Supplemental Figure 4 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Gaspar Aspas Requena, Aishwarya Sahasrabudhe, Elie Traer, Maël Heiblig et al.
Acute Myeloid Leukemia Research
article

Supplemental Figure 4 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

Gaspar Aspas Requena, Aishwarya Sahasrabudhe, Elie Traer, Maël Heiblig, Emmanuelle Tavernier, Brandon Hayes‐Lattin, Daniel T. Peters, Christopher A. Eide, Theodore P. Braun, Daniel A. Pollyea, Ronan Swords, Jessica Leonard, Ashley M. Eckel, Joshua F. Zeidner, Arpita P. Gandhi, Maria L. Amaya, Jennifer N. Saultz, Nicola Long, Andy Kaempf, Gabrielle Meyers, Jeffrey Tyner, Michael R. Loken, Christine M. McMahon, Rachel J. Cook, Stephen E. Kurtz, Anupriya Agarwal, Wei Xie, Richard T. Maziarz, Curtis A. Lachowiez, Jacob Fang, Fangyan Dai, Amenech B. Ashango
article en

Abstract

<p>Overall survival in the subgroup of patients not receiving allogeneic cell transplantation (HCT) based on (A) monocytic vs. non-monocytic differentiation, (B) monocytic differentiation and NPM1 mutation status, (C) in the subgroup of patients with RAS pathway and FLT3-ITD mutations (K/NRAS, PTPN11, FLT3-ITD) and wild-type IDH1/2, NPM1, and TP53; (D) within the patient subgroup classified as mPRS higher-benefit (wild-type for FLT3, N/KRAS and TP53). Reported p-values utilized the cox model Wald test.</p>

Openalex Percentile: Top 70%
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.